Floatz logo

Asciminib

Blastic Transformation of Chronic Myeloid Leukemia

The University of Hong KongSmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

42 Active assets in the Blastic Transformation of Chronic Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Fludarabine
Ohio State University Comprehensive Cancer Center
Phase 2BBB
Cyclophosphamide
Ohio State University Comprehensive Cancer Center
Phase 2BBB
Imatinib
The University of Hong Kong
Phase 2BB
TACROLIMUS
University of Michigan Rogel Cancer Center
Phase 2BB
METHOTREXATE
University of Michigan Rogel Cancer Center
Phase 2BB

View all 50 →

Same molecule, other indications

Asciminib is also rated in:

B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
B
Indicative ·
62 / 100
View asset →
disease related to hematopoietic stem cell transplantDormant
CCC
Indicative ·
53 / 100
View asset →
Malignant Solid TumorsDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →